Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 3473

Next Previous
X
Search
Drug Profile

TQB 3473

Alternative Names: TQB-3473

Latest Information Update: 28 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Idiopathic thrombocytopenic purpura
  • No development reported Haematological malignancies

Most Recent Events

  • 24 Jan 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase-III trial for Idiopathic thrombocytopenic purpura
  • 07 Dec 2024 Phase-I clinical trials in Idiopathic thrombocytopenic purpura (Second-line therapy or greater) (PO) prior to December 2024
  • 07 Dec 2024 Adverse events and efficacy data from a phase-I trial in Immune thrombocytopenia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top